Squarepoint
KLDO

Squarepoint’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Squarepoint’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,088
Closed -$267K – 3398
2020
Q3 		$267K Buy
+24,088
New +$167K ﹤0.01% 1888

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's KLDO Position: Q4 2020 in Review

Squarepoint sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2020, closing a stake of 24,088 shares — an estimated $267K sold.

Squarepoint first reported a position in KLDO in Q3 2020 and held it in 1 quarter. The position peaked at $267K in Q3 2020. 61 funds tracked by Wall St. Rank hold KLDO as of Q4 2020.

  • Squarepoint reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Squarepoint sold 24,088 Kaleido Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $267K.
  • Squarepoint first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Squarepoint's Kaleido Biosciences, Inc. Common Stock position peaked at $267K in Q3 2020.
  • 61 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2020.

Based on Squarepoint's 13F filing for Q4 2020, filed 16 Feb 2021.